Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
Checked against the public recordLast updated Dec 16, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Mirati Therapeutics Inc.
- Interventions being studied
- Drug: MRTX849; Drug: BI 1701963
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 1b must be either Non-Small Cell Lung Cancer or Colorectal Cancer) * Unresectable or metastatic disease * No available treatment with curative intent * Adequate organ function Exclusion Criteria: * History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow * Other active cancer * Cardiac abnormalities
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Washington University School of MedicineSt Louis, Missouri
- The Cleveland Clinic FoundationCleveland, Ohio
- MD Anderson Cancer CenterHouston, Texas
- Next OncologySan Antonio, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 16, 2024. Always confirm current availability with the study team.